Table 3 PPVs of ESBL positivity for AMR in isolates.

From: Evaluation of three protocols for direct susceptibility testing for gram negative-Enterobacteriaceae from patient samples in Uganda with SMS reporting

Isolate no

Antibiotic

C

SXT

CRO

N

CAZ

TPZ

CTX

AMC

AMP

CXM

AZT

MEM

CN

CIP

1

I

R

R

S

R

I

R

S

R

R

R

S

I

S

2

S

R

R

S

R

S

R

R

R

R

R

S

S

S

3

S

R

R

I

R

I

R

S

R

R

R

S

I

I

4a

R

R

R

R

R

R

R

R

R

R

R

S

R

R

4b

R

R

R

S

R

I

R

R

R

R

R

S

R

R

5a

S

R

R

S

R

S

R

S

R

R

R

S

S

I

5b

S

R

R

S

R

S

R

S

R

R

R

S

S

S

6

R

R

S

S

S

R

R

R

R

I

R

S

S

S

7a

S

R

R

S

R

S

R

S

R

R

R

S

I

I

7b

S

R

R

S

R

S

R

S

R

R

R

S

S

S

8a

S

R

R

S

R

S

R

R

R

R

R

S

S

S

8b

S

R

R

S

R

S

R

S

R

R

R

S

S

S

9

R

R

R

S

R

R

R

R

R

R

R

S

S

S

10

S

R

R

I

R

S

R

R

R

R

R

S

I

I

11

R

R

R

S

I

I

R

S

R

R

R

S

S

S

12

R

R

R

S

I

S

R

R

R

R

R

S

S

R

13

S

R

R

S

R

S

R

R

R

R

R

S

S

I

14

R

R

R

R

R

S

R

I

R

R

R

S

R

S

15

S

R

R

S

I

S

R

S

R

R

R

S

S

S

16

R

R

R

I

R

R

R

R

R

R

R

S

S

R

17a

S

R

R

S

I

I

R

R

R

R

R

S

I

R

17b

S

R

R

I

S

S

R

R

R

R

R

S

R

R

18a

S

R

R

S

R

S

R

R

R

R

R

S

R

R

18b

S

R

R

S

R

S

R

S

R

R

R

S

R

R

19

S

R

R

S

R

S

R

S

R

R

R

S

S

S

20

R

S

S

S

S

I

R

R

R

I

R

S

I

I

21

S

S

R

S

R

S

R

I

R

R

R

S

R

R

22

I

R

R

S

R

I

R

R

R

R

R

S

R

R

23

S

S

R

S

R

I

R

R

R

R

R

S

R

R

24

S

R

R

I

R

S

R

I

R

R

R

S

R

R

25

S

R

R

S

R

I

R

R

R

R

R

S

R

R

26

S

R

R

S

S

S

R

R

R

R

R

S

S

I

27a

S

R

R

S

R

S

R

S

R

R

R

S

S

S

27b

S

R

R

S

R

S

R

R

R

R

R

S

R

R

28a

S

R

R

S

R

R

R

R

R

R

R

S

R

R

28b

S

R

R

S

S

R

R

R

R

R

R

S

R

R

29

S

R

R

S

R

R

R

R

R

R

R

S

R

R

30

S

R

R

S

R

S

R

S

R

R

R

S

R

R

31

R

R

R

S

R

S

R

S

R

R

R

S

R

R

32

R

R

R

S

R

S

R

S

R

R

R

S

S

S

33

R

S

R

S

R

S

R

R

R

R

R

S

S

R

34

R

R

R

S

R

R

R

R

R

R

R

S

R

R

35

S

R

R

S

R

S

R

R

R

R

R

S

R

R

36

R

S

R

I

R

I

R

R

R

R

R

S

R

I

37

S

R

R

R

R

I

R

S

R

R

R

S

S

R

38

R

R

R

R

R

R

R

I

R

R

R

S

R

R

39

R

R

R

R

R

R

R

R

R

R

R

S

R

R

40

R

S

S

S

S

R

R

R

R

R

R

S

S

R

41

R

S

S

S

S

R

R

R

R

R

R

S

R

S

42a

R

R

R

S

S

S

R

R

R

R

R

S

S

I

42b

S

R

R

R

R

S

R

I

R

R

R

S

R

R

43

R

R

R

S

R

S

R

I

R

R

R

S

S

R

44

S

R

R

I

R

R

R

R

R

R

R

S

R

R

45

R

R

R

I

R

I

R

R

R

R

R

S

R

R

Total R

21

47

50

6

42

13

54

32

54

52

54

0

26

30

PPV (%)

39

87*

93*

11

78*

24

100*

60

100*

96*

100*

0

48

55

  1. C Chloramphenicol; SXT Trimethoprim sulfamethoxazole; CRO Ceftriaxone; N Nitrofurantoin; CAZ Ceftazidime; TPZ Piperacillin tazobactam; CTX Cefotaxime; AMC Amoxicillin clavulanate; AMP Ampicillin; CXM Cefuroxime; AZT Aztreonam; MEM Meropenem; CN Gentamicin; CIP Ciprofloxacin; R Resistant; I Intermediate; Sensitive; PPV Positive predictive value.
  2. *Significant PPV.